Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

New System Breaks Technology and Cost Barriers for High-Throughput Large-Genome Sequencing

By BiotechDaily International staff writers
Posted on 28 Jan 2014
Image: The HiSeq X Ten, composed of 10 HiSeq X Systems, breaks the USD 1000 barrier for a 30x human genome, enabling population-scale projects on genotypic variation to understand and improve human health (Photo courtesy of Illumina).
Image: The HiSeq X Ten, composed of 10 HiSeq X Systems, breaks the USD 1000 barrier for a 30x human genome, enabling population-scale projects on genotypic variation to understand and improve human health (Photo courtesy of Illumina).
A new DNA sequencing system utilizes advanced design features to generate massive throughput and enable the world's first USD 1000 human genome sequence.

This achievement has been reached with the new HiSeq X Ten Sequencing System from Illumina (San Diego, CA, USA). The platform includes technology breakthroughs that enable researchers to undertake population and disease studies of unprecedented scale by providing the throughput to sequence tens of thousands of human whole genomes in a single year in a single lab. The HiSeq X Ten is the world’s first platform to deliver high quality, high-coverage human genome sequences for less than USD 1,000—inclusive of typical instrument depreciation, DNA extraction, library preparation, and estimated labor.

Purpose-built for population-scale human whole genome sequencing, the HiSeq X Ten is a platform especially suitable for scientists and institutions focused on the discovery of genotypic variation to enable a deeper understanding of biology and disease. It can deliver a comprehensive catalog of human variation within and outside of coding regions. “The ability to explore the human genome on this scale will bring the study of cancer and complex diseases to a new level. Breaking the ‘sound barrier’ of human genetics not only pushes us through a psychological milestone, it enables projects of unprecedented scale. We are excited to see what lies on the other side,” said Jay Flatley, CEO, Illumina.

Building on the proven performance of Illumina sequencing-by-synthesis (SBS) technology, HiSeq X Ten utilizes a number of advanced design features to generate massive throughput. Patterned flow cells (which contain billions of nanowells at fixed locations) combined with a new clustering chemistry deliver a significant increase in data density (6 billion clusters per run). Using state-of-the art optics and faster chemistry, HiSeq X Ten can process sequencing flow cells more quickly than ever before – generating a 10x increase in daily throughput when compared to current HiSeq 2500 performance. The HiSeq X Ten is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than 3 days or up to 600 gigabases (Gb) per day, per system.

Initial users of the transformative HiSeq X Ten System include Macrogen (Seoul, Republic of Korea) and its CLIA laboratory (Rockville, MD, USA), the Broad Institute (Cambridge, MA, USA), and the Garvan Institute of Medical Research (Sydney, Australia).

“The sequencing capacity and economies of scale of the HiSeq X Ten facility will also allow Garvan to accelerate the introduction of clinical genomics and next-generation medicine in Australia,” said Prof. John Mattick, Executive Director of the Garvan Institute of Medical Research.

Eric Lander, founding director of the Broad Institute and professor of biology at MIT, said, “The HiSeq X Ten should give us the ability to analyze complete genomic information from huge sample populations. Over the next few years, we have an opportunity to learn as much about the genetics of human disease as we have learned in the history of medicine.”

“Macrogen will deploy this groundbreaking technology to open a new era of large-scale, whole genome sequencing in our certified CLIA laboratory,” said Dr. Jeong-Sun Seo, Chairman of Macrogen; “Additionally, we will use the HiSeq X Ten to continue our collaboration with the Genomic Medicine Institute of Seoul National University focused on sequencing Asian populations in order to build a genomics database for use in medical research and healthcare applications.”

Related Links:

Illumina



Channels

Genomics/Proteomics

view channel
Image: The photo shows a mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining. Glucagon is labeled in red and the nuclei in blue (Photo courtesy of Wikimedia Commons).

Regenerative Potential Is a Trait of Mature Tissues, Not an Innate Feature of Newly Born Cells

Diabetes researchers have found that the ability of insulin-producing beta cells to replicate and respond to elevated glucose concentrations is absent in very young animals and does not appear until after weaning.... Read more

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.